MBX Biosciences touts canvuparatide Phase III, once-monthly obesity peptides
At Stifel's virtual cardiometabolic forum, the company pointed to early data on once-monthly obesity candidates alongside its rare endocrinology pipeline.
TR
By Tom Reyes · Markets Editor
Sep 30 12:06 ETSource: TradingView
The wire
- 01In a Stifel 2026 Virtual Cardiometabolic Forum appearance, MBX Biosciences said Phase III work on canvuparatide is underway and described early data for once-monthly obesity peptides.
- 02Long-acting peptide PK profiles would change dosing cadence expectations for clinicians handling rare endocrine disease and obesity, where weekly injections are now the norm.
- 03The remarks come from an investor transcript, not a published readout; no efficacy numbers, patient counts or timelines were disclosed.
From the source
Read at tradingview.comMBX: Advancing once-weekly and once-monthly peptide therapies with strong clinical and market momentum
The forum highlighted a robust pipeline in rare endocrinology and obesity, with phase III for canvuparatide underway and promising early data for once-monthly obesity therapies. The platform's unique PK profiles and multi-mechanism molecules aim to address unmet needs and market segments.
